Apoptosis deregulation influences chemoresistance to azaguanine in human leukemic cell lines

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 331-342

  Sarmento Ribeiro, A B ^a,b   Dourado, M ^a,b   Paiva, A ^b,c   Freitas, A ^c   Silva, T ^a   Regateiro, F ^b,c   Oliveira, C R ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Center of Histocompatibility   (Portugal)

Author keywords

Apoptosis necrosis; Azaguanine cytotoxicity; Chemoresistance; Lymphoid leukemia; Oxidative stress

Indexed keywords

8 AZAGUANINE; DAUNORUBICIN; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CROSS RESISTANCE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZAGUANINE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA;

EID: 84861064729     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.659925     Document Type: Article

References (54)

1. Duke RC, Ojcius DM, Young JDE. Cell suicide in health and disease. Sci Am 1996;275(6):80-87.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
3. Tanuma SI. Molecular mechanisms of apoptosis. In: Sluyser M (eds.). Apoptosis inNormalDevelopment and Cancer. Bristol, PA: Taylor and Francis; 1996, 39-59.
4. Fulda S, Debatin KM. Apoptosis in drug response. Curr Pharmacogenomics 2003;1(1):9-16.
5. Reed JC. Apoptosis and cancer: strategies for integrating programmed cell death. Semin Hematol 2000;37(4):9-16
6. Gorman A, Samali A, McGowan A, Cotter T. Use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry 1997;29:97-105. (Pubitemid 27444658)
7. Aubry J-P, Blaeccke A, Lecoanet-Henchoz S, Jeannin P, Herbault N, Caron G,Moine V, Bonnefoy J-Y. Annexin V used formeasuring apoptosis in the early events of cellular cytotoxicity. Cytometry 1999;37:197-204. (Pubitemid 29504086)
8. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997;27: 1-20. (Pubitemid 27059777)
9. KoopmanG, ReutelingspergerCPM, KuitjenGAM.Anexina V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994;84(5):1415-1420. (Pubitemid 24273007)
10. Bartkowiak D, Stephanie H, Heinrich B, Nothdurf WR, Öttinger EM. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999;37: 191-196. (Pubitemid 29504085)
11. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178. (Pubitemid 43076714)
12. Dörthe OH, Ulrich G, Hans JS, Ulrike BG, Norbert J, Peter G, Gritta EJ-S.Thioguanine offers no advantage overmercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003;102(8):2736-2740.
13. Colsky J,Meiselas LE, Rosen SJ, Schulman I. Response of patients with leukemia to 8-azaguanine. Blood 1955;10:482-492.
14. Dourado M, Sarmento AB, Vale Pereira S, Alves V, Silva T, Mota Pinto A, Santos Rosa M. CD26/DPPIV expression and 8- azaguanine response in T-acute lymphoblastic leukaemia cell lines in culture. Pathophysiology 2007;14:3-10. (Pubitemid 46636220)
15. Kolata G. Why do cancer cells resist drugs. Science 1986;231: 220-221.
16. Kartner N, Ling V. Multidrug resistance in cancer. Sci Am 1989:26-33.
17. Ramu A, Pollard HB, Rosário LM. Doxorubicin resistance in p388 leukemia-evidence for reduced drug influx. Int J Cancer 1989;44:539-547. (Pubitemid 19229318)
18. Burdon RH. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med 1995;18(4):775-794.
19. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. Febs Lett 1995;358:1-3.
20. McKenna SL, Padua RA. Multidrug resistance in leukaemia. Br J Haematol 1997;96:659-674. (Pubitemid 27115858)
21. Aguila JF, Ramos OC, Vázquez RP. Mecanismos de resistencia a la terapia citotóxica. Sangre 1998;45(5):406-414.
22. Oberley TD, Schultz JL, Li N, Oberley LW. Antioxidant enzyme levels as a function of growth state in cell culture. Free Radic Biol Med 1995;19(1):53-65.
23. Susuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med 1997;22(1-2):269-281.
24. Freeman BA, Crapo JD. Biology of disease. Free radicals and tissue injury. Lab Invest 1982;47(5):412-426. (Pubitemid 13229679)
25. Southorn PA, Powis G. Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc 1988;63:390-408.
26. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine, 2nd edition. Oxford: Clarendon Press, 1989, 543.
27. Sinha BK, Mimnaugh EG. Free radical and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Rad Biol Med 1990;8:567-581. (Pubitemid 20204420)
28. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999;49:91-102. (Pubitemid 29133467)
29. O'Connor JH. Flow cytometry versus fluorescencemicroscopy. In Fluorescence Microscopy and Fluorescent Probes, J Slavík (ed.). New York: Plenum Press, 1996, 61-66.
30. Orfao A, Schmitz G, Brando B, Ruiz AA, Basso G, Braylan R, Rothe G, Lacombe F, Lanza F, Papa S, Lucio P, San Miguel JF. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999;45(10):1708-1717. (Pubitemid 29477326)
31. Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RN. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res 1979;39:402-407. (Pubitemid 9095899)
32. Sarmento Ribeiro AB. Alterações fenotípicas da célula tumoral e a sua relação com a resist̂encia á quimioterapia. PhD thesis, University of Coimbra, Coimbra, 2002.
33. Nfrgaard MJ, Hockland P. Biology of multiple drug resistance in acute leukaemia. Int J Hematol 2000;72:290-297.
34. Whitlock JA. Principles and pharmacology of chemotherapy. In Wintrobe's Clinical Hematology, Volume 2, 10th edition. Ed. Lee GR, Foerster J, Lukens J, Paraskevas F, greer JP, Rodgers GM. Philadelphia, 540 PA: Williams & Wilkins, Cap. 82, 1999, 2076-2101.
35. Ramu A, Glaubiger D, Weintraub H. Differences in lipid composition of doxorubicin-sensitive and resistant P388 cells. Cancer Treat Rep 1984;68(4):637-641. (Pubitemid 14144355)
36. Dumontet C, Fabianowska-Majewska K, Mantincic D, Bauchu EC, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A,Mackey J. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol 1999;106:78-85. (Pubitemid 29343530)
37. Gillin FD, Roufa DJ, Beadet AL, Caskey CT. 8-Azaguanine resistance in mammalian cells. I. Hypoxanthine-guanine phosphoribosyltransferase. Genetics 1972;72:239-252.
38. Löfgreen C, Hjortsberg L, Blennow M, Lofti K, Paul C, Eriksson S, Albertioni F. Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicine in leukemic cells. Bioch Biophys Res Comm 2004;320:825-832. (Pubitemid 38887217)
39. Buttke TM, SandstromPA. Oxidative stress as amediator of apoptosis. Immunol Today 1994;15(1):7-10.
40. Gardner AM, Xu FH, Fady C, Jacoby FJ, Duffey DC, Tu Y, Lichtenstein A. Apoptotic vs. nonapoptotic cytotoxicity induced by hydrogen peroxide. Free Radic Biol Med 1997;22(1-2):73-83.
41. Lepoivre M, Fieshi F, Coves J,Thelander L, Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun 1991;179(1):442-448.
42. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase bymacrophage-derived nitric oxide. J ExpMed 1991;174:761-767.
43. Takagi K, Isobe Y, Yasukawa K, Okouchi E, Suketa Y. Nitric oxide blocks the cell cycle of mouse macrophage-like cells in the early G2+M phase. FEBS Lett 1994;340:159-162. (Pubitemid 24080940)
44. Bettäieb A, Plo I, Mas VM, Mary AQ, Levade T, Laurent G, Jaffrézou JP. Daunorubicin- and mitoxantrone-triggered phosphatidylcholine hydrolysis: implication in drug-induced ceramid generation and apoptosis. Mol Pharmacol 1999;55:118-125.
45. Toshiyuki M, Reed JC. Bcl-2 oncoprotein blocks chemotherapyinduced apoptosis in a human leukemia cell line. Blood 1993;81(1):151-157. (Pubitemid 23013689)
46. Labroille G, Dumain P, Lacombe F, Belloc F. Flow cytometric evaluation of Fas expression in relation to response and resistance to anthracyclines in leukemic cells. Cytometry 2000;39: 195-202. (Pubitemid 30123853)
47. Rivest RS, Irwin D, Mandel HG. Inhibition of initiation of translation in L1210 cells by 8-azaguanine. Biochem Pharmacol 1982;31(15):2505-2511. (Pubitemid 12095310)
48. Jia L, Allen PD, Macey MG, Grahn MF, Newland AC, Kelsey SM. Mitochondrial electron transport chain activity, but not ATP synthesis, is required for drug-induced apoptosis in human leukaemia cells: a possible novel mechanism of regulating drug resistance. Br J Haematol 1997;98:686-698. (Pubitemid 27386552)
49. Tu Y, Xu F-H, Liu J, Vescio R, Berenson J, Fady C, Lichetenstein A. Upregulated expression of Bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood 1996;88(5):1805-1812. (Pubitemid 26307078)
50. Lee YJ, Shacter E. Bcl-2 does not protect Burkitt's lymphoma cells from oxidant-induced cell death. Blood 1997;89(12):4480-4492. (Pubitemid 27260258)
51. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, örd T, Bredesen DE. Bcl-2 inhibition of neutral death: decreased generation of reactive oxygen species. Science 1993;262:1274-1277. (Pubitemid 24036095)
52. Baker AF, Briehl MM, Dorr R, Powis G. Decreased antioxidant defence and increased oxidant stress during dexamethasoneinduced apoptosis: bcl-2 prevents the loss of antioxidant enzyme activity. Cell Death Differ 1996;3:207-213. (Pubitemid 26167150)
53. Esposti MD, Hatzinisiriou I, McLennan H, Ralph S. Bcl-2 and mitochondrial oxygen radicals. J Biol Chem 1999;274(42): 29831-29837.
54. Schimmer AD, Hedley DW, Penn ZZLZ, Minden MD. Receptorandmitochondrial- mediated apoptosis inacute leukemia: a translational view. Blood 2001;98(13):3541-3553.